VTGN

2.39

1.44% -0.035

Vorhandelsmarkt: 2.39

Vistagen Therapeutics Inc (VTGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.425

Offen:

$2.41

24-Stunden-Volumen:

95,468

Relative Volume:

0.75

Marktkapitalisierung:

$68.98M

Einnahmen:

$875.70K

Nettoeinkommen (Verlust:

$-39.57M

KGV:

-1.7805

EPS:

-1.3423

Netto-Cashflow:

$-33.65M

1W Leistung:

-1.65%

1M Leistung:

+0.63%

6M Leistung:

-11.48%

1J Leistung:

-39.19%

1-Tages-Spanne:

$2.33

$2.45

1-Wochen-Bereich:

$2.31

$2.63

52-Wochen-Spanne:

$1.90

$4.21

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Firmenname

Vistagen Therapeutics Inc

Sektor

Healthcare (1169)

Branche

Biotechnology (665)

Telefon

650-577-3600

Adresse

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Mitarbeiter

Twitter

@vistagen

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

VTGN's Discussions on Twitter

Vergleichen Sie VTGN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VTGN Vistagen Therapeutics Inc	2.39	70.13M	875.70K	-39.57M	-33.65M	-1.3423
ONC Beone Medicines Ltd Adr	251.72	25.78B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	446.48	114.53B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.3401	40.54M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	84.81	6.44B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	487.86	65.13B	14.09B	4.50B	2.96B	39.28

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-07	Hochstufung	Jefferies	Hold → Buy
2023-08-07	Hochstufung	Maxim Group	Hold → Buy
2022-07-22	Herabstufung	Jefferies	Buy → Hold
2022-07-22	Herabstufung	Robert W. Baird	Outperform → Neutral
2022-07-22	Herabstufung	William Blair	Outperform → Mkt Perform
2021-05-20	Eingeleitet	Robert W. Baird	Outperform
2021-02-18	Eingeleitet	Jefferies	Buy
2021-01-04	Hochstufung	William Blair	Mkt Perform → Outperform
2018-06-27	Eingeleitet	Maxim Group	Buy
2018-02-08	Bestätigt	Chardan Capital Markets	Buy
2017-03-28	Eingeleitet	Maxim Group	Buy

Alle ansehen

Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten

03:10 AM

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Northern Trust Corp - Defense World

03:10 AM

Jun 03, 2025

Vistagen expects phase 3 trial results by 2026 By Investing.com - Investing.com South Africa

Jun 03, 2025

Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial - marketscreener.com

Jun 02, 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year - Yahoo Finance

Jun 02, 2025

May 31, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat

May 31, 2025

May 28, 2025

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - sharewise

May 28, 2025

Vistagen Showcases Revolutionary Nose-to-Brain Drug Technology at Major Jefferies Healthcare Conference - Stock Titan

May 28, 2025

May 23, 2025

Breakthrough Nasal Spray Treatment Shows Promise for Depression and Social Anxiety, New Clinical Data Reveals - Stock Titan

May 23, 2025

May 11, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Renaissance Technologies LLC - MarketBeat

May 11, 2025

May 08, 2025

254,655 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Bought by Almitas Capital LLC - MarketBeat

May 08, 2025

May 06, 2025

Renaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

May 06, 2025

May 05, 2025

Form 8-KCurrent report - ADVFN

May 05, 2025

May 04, 2025

Nantahala Capital Management LLC Boosts Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

May 04, 2025

Apr 29, 2025

JPMorgan Chase & Co. Buys 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

Apr 29, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 24, 2025

JPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Apr 24, 2025

Apr 17, 2025

Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan

Apr 17, 2025

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - BioSpace

Apr 17, 2025

Apr 08, 2025

Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World

Apr 08, 2025

Apr 06, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Purchased by Blair William & Co. IL - Defense World

Apr 06, 2025

Apr 04, 2025

VTGN Stock Touches 52-Week Low at $2.21 Amid Market Challenges - Investing.com UK

Apr 04, 2025

Apr 03, 2025

VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire

Apr 03, 2025

Mental Disorder Treatment Market Set to Witness Significant - openPR.com

Apr 03, 2025

Mar 24, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat

Mar 24, 2025

Mar 21, 2025

Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR.com

Mar 21, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell? - Defense World

Mar 21, 2025

Mar 19, 2025

Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Sharewise

Mar 19, 2025

Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - StockTitan

Mar 19, 2025

Mar 14, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat

Mar 14, 2025

Mar 12, 2025